KERN - Akerna Corp.
NASDAQ
->
Healthcare
->
Health Information Services
Denver,
United States
Type: Equity
KERN price evolution
KERN
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.33 | $1.38 | $0.88 | $9.5 |
| Short term investments | ||||
| Net receivables | $0.25 | $0.34 | $1.22 | $1.37 |
| Inventory | ||||
| Total current assets | $2.41 | $2.71 | $14.89 | $13.2 |
| Long term investments | $0.23 | |||
| Property, plant & equipment | $0.03 | $0.04 | $0.05 | $0.12 |
| Goodwill & intangible assets | $3.97 | $4.24 | $4.53 | $32.04 |
| Total noncurrent assets | $4.01 | $4.28 | $4.58 | $32.39 |
| Total investments | $0.23 | |||
| Total assets | $6.41 | $7 | $19.47 | $45.59 |
| Current liabilities | ||||
| Accounts payable | $4 | $3.8 | $1.51 | $7.93 |
| Deferred revenue | $0.31 | $0.52 | $0.73 | $2.65 |
| Short long term debt | $7.77 | $6.89 | $13.2 | $9.9 |
| Total current liabilities | $12.08 | $11.21 | $22.73 | $19.99 |
| Long term debt | $2.49 | $1.58 | $1.41 | $4.58 |
| Total noncurrent liabilities | $2.49 | $1.58 | $1.57 | $5.51 |
| Total debt | $10.27 | $8.46 | $14.61 | $14.47 |
| Total liabilities | $14.57 | $12.78 | $24.29 | $25.5 |
| Shareholders' equity | ||||
| Retained earnings | -$173.12 | -$170.04 | -$167.57 | -$142.33 |
| Other shareholder equity | $0.34 | $0.35 | $0.35 | $0.36 |
| Total shareholder equity | -$8.16 | -$5.79 | -$4.83 | $20.09 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.88 | $14.44 | $24.66 | $22.37 |
| Short term investments | ||||
| Net receivables | $1.22 | $1.4 | $1.86 | $1.58 |
| Inventory | ||||
| Total current assets | $14.89 | $18.23 | $27.73 | $24.52 |
| Long term investments | $0.23 | $0.25 | ||
| Property, plant & equipment | $0.05 | $0.15 | $0.13 | |
| Goodwill & intangible assets | $4.53 | $75.86 | $30.38 | |
| Total noncurrent assets | $4.58 | $76.25 | $30.8 | $58.45 |
| Total investments | $0.23 | $0.25 | ||
| Total assets | $19.47 | $94.48 | $58.53 | $24.52 |
| Current liabilities | ||||
| Accounts payable | $1.51 | $12.36 | $5.25 | $1.32 |
| Deferred revenue | $0.73 | $4.13 | $0.37 | $0.62 |
| Short long term debt | $13.2 | $13.2 | $6.14 | |
| Total current liabilities | $22.73 | $29.17 | $11.75 | $2.44 |
| Long term debt | $1.41 | $4.11 | $10.2 | |
| Total noncurrent liabilities | $1.57 | $5.36 | $10.2 | $53.08 |
| Total debt | $14.61 | $17.3 | $16.34 | |
| Total liabilities | $24.29 | $34.53 | $21.96 | $2.44 |
| Shareholders' equity | ||||
| Retained earnings | -$167.57 | -$88.51 | -$41.1 | -$25.25 |
| Other shareholder equity | $0.35 | $0.06 | $0.06 | |
| Total shareholder equity | -$4.83 | $59.95 | $31.87 | $22.08 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.29 | $2.6 | -$4.8 | $5.41 |
| Cost of revenue | $0.96 | $1.05 | -$0.68 | $2.05 |
| Gross Profit | $1.32 | $1.55 | -$4.13 | $3.36 |
| Operating activities | ||||
| Research & development | $0.66 | $0.85 | -$0.55 | $1.37 |
| Selling, general & administrative | $2.15 | $2.34 | -$0.72 | $3.71 |
| Total operating expenses | $3.08 | $3.48 | -$2.38 | $7.2 |
| Operating income | -$1.76 | -$1.93 | -$1.75 | -$3.84 |
| Income from continuing operations | ||||
| EBIT | -$2.85 | -$1.99 | -$25.44 | -$1.95 |
| Income tax expense | -$0.45 | -$0.04 | ||
| Interest expense | $0.23 | $0.49 | $0.24 | $0.4 |
| Net income | ||||
| Net income | -$3.08 | -$2.47 | -$25.23 | -$2.3 |
| Income (for common shares) | -$3.08 | -$2.47 | -$26.19 | -$2.3 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13.65 | $20.68 | $12.57 | $10.92 |
| Cost of revenue | $5.41 | $8.12 | $6.21 | $4.63 |
| Gross Profit | $8.23 | $12.57 | $6.36 | $6.29 |
| Operating activities | ||||
| Research & development | $4.69 | $6.27 | $3.21 | $5.57 |
| Selling, general & administrative | $14.4 | $19.53 | $19.11 | $13.14 |
| Total operating expenses | $63.68 | $45.92 | $23.64 | $18.7 |
| Operating income | -$55.45 | -$33.36 | -$17.27 | -$12.42 |
| Income from continuing operations | ||||
| EBIT | -$78.92 | -$32.06 | -$15.66 | -$12.4 |
| Income tax expense | -$0.72 | -$2.26 | $0.03 | |
| Interest expense | $0.85 | $1.53 | -$0.16 | -$0.09 |
| Net income | ||||
| Net income | -$79.06 | -$31.33 | -$15.53 | -$12.31 |
| Income (for common shares) | -$80.01 | -$31.33 | -$15.53 | -$12.31 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$3.08 | -$2.47 | -$25.23 | -$2.3 |
| Operating activities | ||||
| Depreciation | $0.28 | $0.32 | $1.74 | $2.12 |
| Business acquisitions & disposals | $0.6 | |||
| Stock-based compensation | $0.11 | $0.11 | $0.18 | $0.22 |
| Total cash flows from operations | -$1.55 | -$2.54 | -$0.45 | -$3.26 |
| Investing activities | ||||
| Capital expenditures | -$1.03 | -$1.59 | ||
| Investments | $0.01 | |||
| Total cash flows from investing | $0.6 | -$1.02 | -$1.59 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.5 | $1.09 | $9.18 | |
| Net borrowings | $1 | -$4.92 | $0.08 | |
| Total cash flows from financing | $1.5 | -$4.92 | $0.14 | $9.26 |
| Effect of exchange rate | -$0 | $0.05 | $0.01 | -$0.05 |
| Change in cash and equivalents | -$0.05 | -$6.8 | -$1.32 | $4.37 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$79.06 | -$31.33 | -$15.53 | -$12.31 |
| Operating activities | ||||
| Depreciation | $7.83 | $5.74 | $1.32 | |
| Business acquisitions & disposals | $0.4 | -$5.02 | -$0.09 | $18.84 |
| Stock-based compensation | $0.87 | $2.07 | $1.17 | $3.88 |
| Total cash flows from operations | -$10.9 | -$8.17 | -$14.35 | -$9.05 |
| Investing activities | ||||
| Capital expenditures | -$4.38 | -$5.47 | -$3.26 | |
| Investments | $0.01 | -$0.25 | ||
| Total cash flows from investing | -$3.97 | -$10.49 | -$3.6 | $18.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $11.03 | $1.83 | $4.25 | $10 |
| Net borrowings | -$1.43 | $13.43 | $15.99 | |
| Total cash flows from financing | $8.64 | $14.74 | $20.23 | $10 |
| Effect of exchange rate | -$0.02 | $0.02 | ||
| Change in cash and equivalents | -$6.26 | -$3.9 | $2.29 | $19.79 |
News
|
All You Need to Know About Akerna Corp. (KERN) Rating Upgrade to Buy
Zacks via Yahoo Finance
6 Jun 2023
|
|
Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes
Zacks via Yahoo Finance
20 Mar 2023
|
|
Here's Why You Should Retain Boston Scientific (BSX) Now
Zacks via Yahoo Finance
20 Mar 2023
|
|
Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2
Zacks via Yahoo Finance
17 Mar 2023
|
|
NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth
Zacks via Yahoo Finance
17 Mar 2023
|
|
Abbott (ABT) Diabetes Arm Growth Robust Amid Macroeconomic Woes
Zacks via Yahoo Finance
17 Mar 2023
|
|
Reasons Why You Should Retain ResMed (RMD) Stock For Now
Zacks via Yahoo Finance
16 Mar 2023
|
|
Syneos Health's (SYNH) Product Launch Aids, FX Woe Hurts
Zacks via Yahoo Finance
15 Mar 2023
|
|
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
Zacks via Yahoo Finance
14 Mar 2023
|
|
Henry Schein (HSIC) International Growth Solid, Dental Rebounds
Zacks via Yahoo Finance
14 Mar 2023
|
Fundamentals
| Market cap | $1.54M |
|---|---|
| Enterprise value | $10.48M |
| Shares outstanding | 7.00M |
| Revenue | $5.50M |
|---|---|
| EBITDA | -$27.78M |
| EBIT | -$32.23M |
| Net Income | -$33.10M |
| Revenue Q/Q | -62.41% |
| Revenue Y/Y | -77.83% |
| P/E ratio | -0.05 |
|---|---|
| EV/Sales | 1.91 |
| EV/EBITDA | -0.38 |
| EV/EBIT | -0.33 |
| P/S ratio | 0.28 |
| P/B ratio | -0.18 |
| Book/Share | -1.21 |
| Cash/Share | 0.19 |
| EPS | -$4.73 |
|---|---|
| ROA | -168.71% |
| ROE | -10.03K% |
| Debt/Equity | -5.03 |
|---|---|
| Net debt/EBITDA | -0.48 |
| Current ratio | 0.20 |
| Quick ratio | 0.20 |